YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non–small-cell lung cancer

References

• Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarkas K, Jacob-Hirsch J, Amariglio N, Kupiec M, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485(201–206):201–13. doi:10.1038/nature11112.
   PubMed Web of Science ®Google Scholar
• Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, Yi C, Lindahl T, Pan T, Yang YG, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7(885–887):885–887. doi:10.1038/nchembio.687.
   PubMed Web of Science ®Google Scholar
• Hess ME, Hess S, Meyer KD, Verhagen LA, Koch L, Bronneke HS, Dietrich MO, Jordan SD, Saletore Y, Elemento O, et al. The fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain circuitry. Nat Neurosci. 2013;16(1042–1048):1042–1048. doi:10.1038/nn.3449.
   PubMed Web of Science ®Google Scholar
• Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, Vagbo CB, Shi Y, Wang WL, Song SH, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49(18–29):18–29. doi:10.1016/j.molcel.2012.10.015.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li Y, Toth JI, Petroski MD, Zhang Z, Zhao JC. N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells. Nat Cell Biol. 2014;16(191–198):191–198. doi:10.1038/ncb2902.
   PubMed Web of Science ®Google Scholar
• Fustin JM, M, Yamaguchi Y, Hida H, Nishimura S, Yoshida M, Isagawa T, Morioka MS, Kakeya H, Manabe I, et al. RNA-methylation-dependent RNA processing controls the speed of the circadian clock. Cell. 2013;155(793–806):793–806. doi:10.1016/j.cell.2013.10.026.
   PubMed Web of Science ®Google Scholar
• Zhang C, Fu J, Zhou Y. A review in research progress concerning m6A methylation and immunoregulation. Front Immunol. 2019;10(922). doi:10.3389/fimmu.2019.00922.
   Google Scholar
• Dang W, Xie Y, Cao P, Xin S, Wang J, Li S, Li Y, Lu J. N(6)-methyladenosine and viral infection. Front Microbiol. 2019;10(417). doi:10.3389/fmicb.2019.00417.
   Google Scholar
• Lan Q, Liu PY, Haase J, Bell JL, Huttelmaier S, Liu T. The critical role of RNA m6A methylation in cancer. Cancer Res. 2019;79(1285–1292):1285–1292. doi:10.1158/0008-5472.CAN-18-2965.
   PubMed Web of Science ®Google Scholar
• Patil DP, Pickering BF, Jaffrey SR. Reading m(6)A in the transcriptome: m(6) A-bindingProteins. Trends Cell Biol. 2018;28(113–127). doi:10.1016/j.tcb.2017.10.001.
   PubMedGoogle Scholar
• Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, Weng X, Chen K, Shi H, He C. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell. 2015;161(1388–1399):1388–1399. doi:10.1016/j.cell.2015.05.014.
   PubMed Web of Science ®Google Scholar
• Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Fu Y, Parisien M, Dai Q, Jia G et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(117–120):117–120. doi:10.1038/nature12730.
   PubMed Web of Science ®Google Scholar
• Deng X, Su R, Weng H, Huang H, Li Z, Chen J. RNA N(6)-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018;28(507–517):507–517. doi:10.1038/s41422-018-0034-6.
   PubMed Web of Science ®Google Scholar
• Bai Y, Yang C, Wu R, Huang L, Song S, Li W, Yan P, Lin C, Li D, Zhang Y. YTHDF1 regulates tumorigenicity and cancer stem cell-like activity in human colorectal carcinoma. Front Oncol. 2019;9(332). doi:10.3389/fonc.2019.00332.
   Google Scholar
• Orouji A, Peitsch WK, Orouji A, Houben R, Utikal J. Oncogenic role of an epigenetic reader of m(6)A RNA modification: YTHDF1 in merkel cell carcinoma. Cancers (Basel). 2020;12(1):202. doi:10.3390/cancers12010202.
   PubMed Web of Science ®Google Scholar
• Liu T, Wei Q, Jin J, Luo Q, Liu Y, Yang Y, Cheng C, Li L, Pi J, Si Y, et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res. 2020;48(3816–3831):3816–3831. doi:10.1093/nar/gkaa048.
   PubMedGoogle Scholar
• Zhao X, Chen Y, Mao Q, Jiang X, Jiang W, Chen J, Xu W, Zhong L, Sun X. Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Biomark. 2018;21(859–868):859–868. doi:10.3233/CBM-170791.
   PubMed Web of Science ®Google Scholar
• Jia R, Chai P, Wang S, Sun B, Xu Y, Yang Y, Ge S, Jia R, Yang YG, Fan X. m(6)A modification suppresses ocular melanoma through modulating HINT2 mRNA translation. Mol Cancer. 2019;18(161). doi:10.1186/s12943-019-1088-x.
   Google Scholar
• Li J, Meng S, Xu M, Wang S, He L, Xu X, Wang X, Xie L. Downregulation of N(6)-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N(6)-methyladenosine levels. Oncotarget. 2018;9(3752–3764). doi:10.18632/oncotarget.23365.
   Google Scholar
• Sheng H, Li Z, Su S, Sun W, Zhang X, Li L, Li J, Liu S, Lu B, Zhang S, et al. YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation. Carcinogenesis. 2020;41(541–550):541–550. doi:10.1093/carcin/bgz152.
   PubMed Web of Science ®Google Scholar
• Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, et al. R-2HG exhibits anti-tumor activity by targeting FTO/m(6)A/MYC/CEBPA signaling. Cell. 2018;172(1–2):90–105 e123. doi:10.1016/j.cell.2017.11.031.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(541–550):541–550. doi:10.1038/s41591-018-0014-x.
   PubMed Web of Science ®Google Scholar
• Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75(2139–2145):2139–2145. doi:10.1158/0008-5472.CAN-15-0255.
   PubMed Web of Science ®Google Scholar
• Cao R, Yuan L, Ma B, Wang G, Tian Y. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC). Cancer Immunol Immunother. 2021;70(1–18):1–18. doi:10.1007/s00262-020-02649-x.
   PubMed Web of Science ®Google Scholar
• Datta M, Coussens LM, Nishikawa H, Hodi FS, Jain RK. Reprogramming the tumor microenvironment to improve immunotherapy: Emerging strategies and combination therapies. Am Soc Clin Oncol Educ Book. 2019;39(165–174). doi:10.1200/EDBK_237987.
   PubMedGoogle Scholar
• Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martin-Algarra S, Mandal R, Sharfman WH, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171(4):934–949 e916. doi:10.1016/j.cell.2017.09.028.
   PubMed Web of Science ®Google Scholar
• Liu F, Qin L, Liao Z, Song J, Yuan C, Liu Y, Wang Y, Xu H, Zhang Q, Pei Y, et al. Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma. Exp Hematol Oncol. 2020;9(10). doi:10.1186/s40164-020-00165-3.
   Google Scholar
• Yang S, Wei J, Cui YH, Park G, Shah P, Deng Y, Aplin AE, Lu Z, Hwang S, He C, et al. m(6)A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019;10(2782). doi:10.1038/s41467-019-10669-0.
   Google Scholar
• Inoue Y, Yoshimura K, Mori K, Kurabe N, Kahyo T, Mori H, Kawase A, Tanahashi M, Ogawa H, Inui N, et al. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. Oncotarget. 2016;7(32113–32128):32113–32128. doi:10.18632/oncotarget.8528.
   PubMedGoogle Scholar
• Sugimura H. Detection of chromosome changes in pathology archives: an application of microwave-assisted fluorescence in situ hybridization to human carcinogenesis studies. Carcinogenesis. 2008;29(681–687):681–687. doi:10.1093/carcin/bgn046.
   PubMed Web of Science ®Google Scholar
• Sugimura H, Mori H, Nagura K, Kiyose S, Tao H, Isozaki M, Igarashi H, Shinmura K, Hasegawa A, Kitayama Y, et al. Fluorescence in situ hybridization analysis with a tissue microarray: ‘FISH and chips’ analysis of pathology archives. Pathol Int. 2010;60(543–550):543–550. doi:10.1111/j.1440-1827.2010.02561.x.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G, Garg K, et al. International association for the study of lung cancer/american thoracic society/european respiratory society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011;8(381–385):381–385. doi:10.1513/pats.201107-042ST.
   PubMedGoogle Scholar
• Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260. doi:10.1097/JTO.0000000000000630.
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(39–51):39–51. doi:10.1016/j.jtho.2015.09.009.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Matsuura S, Kurabe N, Kahyo T, Mori H, Kawase A, Karayama M, Inui N, Funai K, Shinmura K, et al. Clinicopathological and survival analysis of japanese patients with resected non-small-cell lung cancer harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA gene amplification. Journal of Thoracic Oncology. 2015;10(1590–1600):1590–1600. doi:10.1097/jto.0000000000000685.
   PubMed Web of Science ®Google Scholar
• Yoshimura K, Inoue Y, Tsuchiya K, Karayama M, Yamada H, Iwashita Y, Kawase A, Tanahashi M, Ogawa H, Inui N, et al. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer. Lung Cancer. 2020;141(21–31):21–31. doi:10.1016/j.lungcan.2020.01.005.
   PubMed Web of Science ®Google Scholar
• Yoshimura K, Suzuki Y, Inoue Y, Tsuchiya K, Karayama M, Iwashita Y, Kahyo T, Kawase A, Tanahashi M, Ogawa H, et al. CD200 and CD200R1 are differentially expressed and have differential prognostic roles in non-small cell lung cancer. Oncoimmunology. 2020;9(1746554):1746554. doi:10.1080/2162402X.2020.1746554.
   PubMed Web of Science ®Google Scholar
• Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn. 2010;12(169–176):169–176. doi:10.2353/jmoldx.2010.090140.
   PubMed Web of Science ®Google Scholar
• Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, Innocenti G, Wetzel R, Crosby K, Becker A, et al. Mutation-specific antibodies for the detection of EGFR mutations in Non–Small-Cell lung cancer. Clin Cancer Res. 2009;15(3023–3028):3023–3028. doi:10.1158/1078-0432.CCR-08-2739.
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013;8(e82241):e82241. doi:10.1371/journal.pone.0082241.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(401–404):401–404. doi:10.1158/2159-8290.CD-12-0095.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(pl1):pl1–pl1. doi:10.1126/scisignal.2004088.
   PubMed Web of Science ®Google Scholar
• Althouse AD. Adjust for multiple comparisons? It’s not that simple. Ann Thorac Surg. 2016;101(1644–1645):1644–1645. doi:10.1016/j.athoracsur.2015.11.024.
   PubMed Web of Science ®Google Scholar
• Shi Y, Fan S, Wu M, Zuo Z, Li X, Jiang L, Shen Q, Xu P, Zeng L, Zhou Y, et al. YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019;10(4892). doi:10.1038/s41467-019-12801-6.
   Google Scholar
• Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, Huang X, Liu Y, Wang J, Dougherty U, et al. Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells. Nature. 2019;566(270–274):270–274. doi:10.1038/s41586-019-0916-x.
   PubMed Web of Science ®Google Scholar